Your browser is no longer supported. Please, upgrade your browser.
Akari Therapeutics, Plc
Index- P/E- EPS (ttm)-0.73 Insider Own26.88% Shs Outstand33.87M Perf Week67.48%
Market Cap105.67M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float18.75M Perf Month72.50%
Income-18.10M PEG- EPS next Q- Inst Own20.80% Short Float0.92% Perf Quarter96.02%
Sales- P/S- EPS this Y12.60% Inst Trans0.74% Short Ratio0.73 Perf Half Y67.48%
Book/sh0.14 P/B24.64 EPS next Y0.00% ROA-161.50% Target Price- Perf Year77.84%
Cash/sh0.40 P/C8.59 EPS next 5Y- ROE-880.40% 52W Range0.87 - 3.19 Perf YTD86.49%
Dividend- P/FCF- EPS past 5Y16.30% ROI- 52W High8.15% Beta1.56
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low296.55% ATR0.23
Employees10 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)89.63 Volatility15.54% 8.61%
OptionableNo Debt/Eq0.00 EPS Q/Q133.10% Profit Margin- Rel Volume3.18 Prev Close3.19
ShortableYes LT Debt/Eq0.00 EarningsDec 11 BMO Payout- Avg Volume235.95K Price3.45
Recom2.00 SMA2070.20% SMA5089.05% SMA20086.61% Volume714,669 Change8.15%
Jan-04-19Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Jan-06-21 09:32AM  
Dec-11-20 09:00AM  
Dec-03-20 10:00AM  
Nov-30-20 11:35PM  
Oct-27-20 09:00AM  
Oct-06-20 08:30AM  
Sep-29-20 09:30AM  
Sep-10-20 08:00AM  
Sep-02-20 06:19AM  
Sep-01-20 08:30AM  
Aug-31-20 07:00AM  
Aug-12-20 08:23AM  
Jul-01-20 09:16AM  
Jun-25-20 11:23AM  
May-29-20 07:00AM  
May-21-20 11:32AM  
May-04-20 07:30AM  
May-01-20 07:00AM  
Mar-31-20 08:00AM  
Mar-04-20 08:52AM  
Feb-21-20 07:46AM  
Feb-20-20 05:34PM  
Jan-27-20 08:58AM  
Jan-10-20 09:30AM  
Dec-23-19 08:45AM  
Dec-02-19 08:30AM  
Nov-18-19 06:09AM  
Nov-04-19 08:33AM  
Oct-14-19 08:37AM  
Oct-10-19 08:45AM  
Oct-06-19 05:15PM  
Sep-19-19 06:54AM  
Sep-18-19 08:00AM  
Sep-16-19 10:29AM  
Sep-13-19 08:00AM  
Sep-04-19 10:02AM  
Sep-03-19 07:00AM  
Sep-02-19 09:17AM  
Aug-30-19 12:51PM  
Aug-29-19 08:06AM  
Aug-15-19 11:55AM  
Aug-14-19 12:27PM  
Aug-09-19 08:30AM  
Jul-31-19 09:57AM  
Jul-17-19 03:00PM  
Jul-04-19 08:35AM  
Jun-28-19 09:22AM  
Jun-21-19 11:05AM  
Jun-20-19 09:35AM  
Jun-19-19 11:24AM  
May-29-19 07:45AM  
Apr-29-19 07:30AM  
Apr-26-19 08:48AM  
Apr-24-19 08:09AM  
Apr-23-19 04:01PM  
Mar-27-19 04:15PM  
Mar-18-19 02:30PM  
Mar-14-19 10:06AM  
Mar-13-19 02:35PM  
Feb-21-19 08:30AM  
Feb-04-19 12:45PM  
Jan-29-19 11:10AM  
Dec-26-18 11:19AM  
Nov-30-18 04:05PM  
Nov-15-18 09:00AM  
Oct-25-18 08:55AM  
Sep-30-18 07:30AM  
Sep-27-18 06:56AM  
Sep-25-18 07:00AM  
Sep-12-18 07:00AM  
Sep-04-18 08:30AM  
Aug-20-18 09:00AM  
Aug-17-18 07:00AM  
Jun-15-18 08:00AM  
May-25-18 07:53PM  
May-21-18 08:00AM  
May-16-18 07:23PM  
Apr-16-18 07:20AM  
Apr-03-18 08:25AM  
Mar-21-18 03:50PM  
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.